Clinical Trial Update: "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update notes the termination of a Phase 1/2 trial evaluating atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting for triple-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• RP1 oncolytic immunotherapy

Snippet

Sponsor: Institut Curie | Conditions: Triple Negative Breast Neoplasms | Phase 1, Phase 2 | Status: TERMINATED